Prediction of progression-free survival in patients with neuroendocrine tumors received 177Lu-Dotatate using circulating biomarkers

#3281

Introduction: Few circulating biomarkers are available for prediction of progression-free survival (PFS) in patients with advanced neuroendocrine tumors (NET) received 177Lu-Dotatate.

Aim(s): To study the role of circulating biomarkers in predicting PFS of patients with advanced NET received 177Lu-Dotatate.

Materials and methods: Data of clinicopathological features and data of baseline circulating biomarkers including blood cell count, erythrocyte sedimentation rate (ESR), liver and kidney function tests and chromogranin A (CgA) of patients with advanced NET received 177Lu-Dotatate were retrospectively collected. Continuous variables were normalized by divided them by their upper normal limits and classification and regression trees was used to determine optimal cut-off value.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chen L, Gnanasegaran G, Mandair D, Toumpanakis C, Caplin M,

Keywords: PRRT, survival, ESR, creatinine, CgA,